bioAffinity Raises $4M in Registered Direct Offering Priced At-The-Market
BIAF sits 75% above its 52-week low of $4.56 on elevated volume (8.2× avg).
Summary
bioAffinity Technologies announced a $4 million registered direct offering of common stock at $6.122 per share, priced at-the-market under Nasdaq rules. The 424B5 prospectus supplement details the offering: 116,545 shares at $6.122, pre-funded warrants for up to 536,836 shares at $0.007 exercise, and concurrent private placement warrants for 980,072 shares at $6.122. Closing is expected October 9, 2026. This follows the company's August private placement of $4.0 million and its recent Nasdaq compliance recovery. The offering is dilutive and comes as the company's cash runway was previously disclosed to end this month, making the capital raise necessary but also a signal of ongoing funding needs.
Updated with an SEC 424B5 filing · What changed
Updates
· SEC 424B5 — The 424B5 prospectus supplement details the offering: 116,545 shares at $6.122, pre-funded warrants for up to 536,836 shares at $0.007 exercise, and concurrent private placement warrants for 980,072 shares at $6.122.
At the time of this announcement, BIAF was trading at $7.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $4.56 to $80.70. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.